This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (9)  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in this journal  Topic Collections  • Dermatology, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

The Uncertainty Persists but the Fog Is Dispersing

Arch Dermatol. 2003;139:85-86.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

THERAPEUTIC STUDIES in toxic epidermal necrolysis (TEN), a rare but dramatic and life-threatening disease, have recently drawn a considerable amount of attention. Despite (or perhaps due to) the fact that a variety of possible therapeutic modalities have been proposed, usually based on a symptomatic approach and tried in single patients or small series, still no proven and widely accepted treatment regimen exists.

The development of a generally accepted treatment strategy has been hampered by the fact that the condition is part of a larger spectrum of reactive inflammatory skin diseases and thus heterogeneous; that it is rare and life threatening and thus precludes placebo-controlled studies; and that our knowledge on the pathogenic mechanisms involved are still only fragmentary.

Following the observation that antibodies present in pooled purified human immunoglobulin blocks Fas-mediated keratinocyte apoptosis in vitro,¹ high-dose intravenous immunoglobulins (IVIG) have been introduced into the treatment of TEN in 1998. In . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLES

Treatment of Toxic Epidermal Necrolysis With High-Dose Intravenous Immunoglobulins: Multicenter Retrospective Analysis of 48 Consecutive Cases
Christa Prins, Francisco A. Kerdel, R. Steven Padilla, Thomas Hunziker, Sergio Chimenti, Isabelle Viard, Davide N. Mauri, Kirsten Flynn, Jennifer Trent, David J. Margolis, Jean-Hilaire Saurat, Lars E. French, and for the TEN-IVIG Study Group
Arch Dermatol. 2003;139(1):26-32.
ABSTRACT | FULL TEXT  

Intravenous Immunoglobulin Treatment for Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Prospective Noncomparative Study Showing No Benefit on Mortality or Progression
Nicolas Bachot, Jean Revuz, and Jean-Claude Roujeau
Arch Dermatol. 2003;139(1):33-36.
ABSTRACT | FULL TEXT  

Analysis of Intravenous Immunoglobulin for the Treatment of Toxic Epidermal Necrolysis Using SCORTEN: The University of Miami Experience
Jennifer T. Trent, Robert S. Kirsner, Paolo Romanelli, and Francisco A. Kerdel
Arch Dermatol. 2003;139(1):39-43.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Intravenous Immunoglobulin for the Treatment of Toxic Epidermal Necrolysis
Trent and Kerdel
Arch Dermatol 2003;139:1081-1081.
FULL TEXT  

IVIg Helps SJS/TEN; No It Doesn't ; Yes It Does
Journal Watch Dermatology 2003;2003:5-5.
FULL TEXT